Bausch + Lomb Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BLCO research report →
Range $17 – $24
Price Chart
About the company
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options.
- CEO
- Thomas J. Appio
- IPO
- 2022
- Employees
- 13,000
- HQ
- Vaughan, ON, CA
Get TickerSpark's AI analysis on BLCO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.93B
- P/E
- -67.73
- Fwd P/E
- 20.49
- PEG
- -0.74
- P/S
- 1.39
- P/B
- 1.16
- EV/EBITDA
- 17.61
- Div Yield
- 0.00%
- Gross Margin
- 58.62%
- Op Margin
- 8.41%
- Net Margin
- -2.05%
- ROE
- -1.73%
- ROIC
- 3.78%
Latest fiscal year · YoY change
- Revenue
- $5.10B+6.5%
- Gross Profit
- $2.79B-4.3%
- Op Income
- $188.00M
- Net Income
- $-360,000,000-13.6%
- EPS
- $-1.02-13.3%
- OCF Growth
- +22.0%
- FCF Growth
- -11.9%
- 52W High
- $21.40
- 52W Low
- $14.54
- 50D MA
- $18.23
- 200D MA
- $16.94
- Beta
- 0.52
- RSI (14)
- 47
- Avg Volume
- 650.80K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Bausch + Lomb delivered broad-based Q3 growth, expanded margins sharply, raised full-year guidance again, and said it is tracking ahead of its long-term margin targets.· October 28, 2026
- Q3 revenue was $1.375 billion, up 8% constant currency, with growth across all three segments.
- Adjusted EBITDA rose 34% to $325 million and margin expanded to 23.6%; adjusted EPS was $0.34 versus $0.18 last year.
- Gross margin reached 64.7%, or 63.6% excluding a one-time tariff refund of about $14 million.
- Full-year 2026 guidance was raised again: revenue to $5.450 billion-$5.550 billion and adjusted EBITDA to $1.090 billion-$1.140 billion.
- Management highlighted strong momentum in Miebo, LUMIFY, contact lenses, and premium IOLs, while emphasizing further SG&A efficiency and pipeline execution.
Total company revenue for Q3 was $1.375 billion, up 8%, with constant currency revenue also up 8%; foreign exchange was a roughly $6 million headwind. Adjusted gross margin was 64.7%, up 300 basis points year over year, or 63.6% excluding a one-time tariff refund of approximately $14 million. Adjusted EBITDA was $325 million, up 34% year over year, with adjusted EBITDA margin at 23.6%, up 460 basis points. Adjusted EPS, excluding acquired in-process R&D, was $0.34 versus $0.18 in the prior-year quarter. Operating cash flow was $233 million and free cash flow was $178 million; net leverage improved to 4.1x from 5.7x a year ago. For full-year 2026, revenue guidance was raised by $10 million to $5.450 billion-$5.550 billion, implying constant-currency growth of about 6.1% to 8.0%. Adjusted EBITDA guidance was raised by $65 million to $1.090 billion-$1.140 billion, with midpoint margin of about 20.3%. Other 2026 assumptions included adjusted gross margin of 62.5%-63%, interest expense of about $365 million, CapEx of about $285 million, and an adjusted tax rate of about 18%.
Tom Appio framed his interim CEO role as a continuation of Vision 27, with a focus on improving profitability, operating more effectively, and continuing to invest in innovation. He said the business has delivered four straight quarters against Investor Day commitments and pointed to growth across pharma, surgical, and vision care as evidence the strategy is working. His tone was confident and pragmatic: keep driving profitable growth, strengthen execution, and allocate capital more rigorously while advancing the pipeline.
Osama A. Eldessouky emphasized that the quarter showed the intended progression from revenue growth to margin expansion to cash generation and lower leverage. He cited $233 million of operating cash flow, $178 million of free cash flow, and net leverage down to 4.1x, calling it the company’s strongest cash-generation quarter since the 2022 IPO. On margins, he highlighted 64.7% gross margin, or 63.6% excluding the tariff refund, and said adjusted SG&A continued to decline, supporting year-to-date improvement of 150 basis points. He also said the company remains confident in reaching its 3.5x leverage target and raised full-year guidance for revenue, EBITDA, gross margin, and tax rate.
Analysts focused first on the leadership transition, asking why a change was made despite strong results; Appio said the board and Brenton mutually agreed on the transition as the company enters its next phase. Questions also centered on how he would manage time and priorities, and Appio answered that the focus will be on Vision 27, customer and patient focus, operational efficiencies, capital allocation, and reducing debt. On segment questions, management said contact lenses are still growing well above the market in the U.S., surgical softness reflected intentional equipment placement strategy rather than demand weakness, and Miebo’s strength is primarily volume-driven with no gross-to-net change for 2026. They also outlined pipeline updates, including dry AMD/tonabersat, Halo, Ilios, EDOF, and dry-eye Phase III planning.
The call showed broad momentum across the portfolio, with double-digit pharma growth, strong contact lens performance, and continued traction in premium surgical offerings. Management sounded increasingly confident that mix improvement, productivity initiatives, and SG&A discipline can sustain margin expansion and support further deleveraging.
The biggest risks discussed were execution and capital allocation discipline, including how to keep improving profitability while funding the pipeline and repaying debt. Some segments still have unevenness: surgical equipment revenue was down because of placement strategy, international contact lens growth was slower, and management acknowledged there may be portfolio gaps or projects that do not work out as planned.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 13.0%
- Shares Outstanding
- 357.50M
- Float Shares
- 46.39M
of shares held by institutions
102 13F filers
Buy/sell ratio 2.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Brookfield Corp | 4.57M | ▲ 4.57M |
| Oaktree Capital Management LP | 3.44M | ▲ 58.30K |
| D. E. Shaw & Co., Inc. | 3.38M | ▲ 56.68K |
| Deutsche Bank AG\ | 3.33M | ▼ 93.79K |
| Davidson Kempner Capital Management LP | 3.16M | 0 |
| Goldentree Asset Management LP | 3.11M | ▲ 446.48K |
| Icahn Carl C | 2.38M | ▼ 1.12M |
| Price T Rowe Associates Inc | 2.23M | ▲ 71.74K |
| Glenview Capital Management, LLC | 1.88M | ▼ 37.74K |
| Arrowstreet Capital, Limited Partnership | 1.55M | ▲ 182.30K |
| Caspian Capital LP | 1.42M | ▼ 576.81K |
| Citadel Advisors LLC | 1.01M | ▲ 20.25K |
Held by 19 ETFs
Biggest fund positions in BLCO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 29, 26 | Munsch Frederick | other | 87,912 |
| Oct 29, 26 | Munsch Frederick | other | 24,103 |
| Oct 29, 26 | Munsch Frederick | sell | 112,015 |
| Oct 29, 26 | Munsch Frederick | other | 87,912 |
| Oct 29, 26 | Munsch Frederick | other | 24,103 |
| Oct 29, 26 | ROBERTSON RUSSEL C | other | 1,256 |
| Oct 29, 26 | Paulson John | other | 1,125 |
| Oct 29, 26 | Alfonso Eduardo | other | 1,125 |
| Aug 12, 26 | Trebbi Barbara | other | 11,776 |
| Aug 5, 26 | Trebbi Barbara | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BLCO coverage
Recent articles, reports, and earnings notes.
No research on BLCO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BLCO report →Bausch + Lomb Corporation (BLCO) Discusses Phase II Results for BL1332 in Ocular Surface Pain Transcript
seekingalpha.com · Nov 20
Bausch + Lomb eye-drop drug misses mid-stage study main goal
reuters.com · Nov 19
Are Medical Stocks Lagging Bausch + Lomb (BLCO) This Year?
zacks.com · Nov 19
Best Growth Stocks to Buy for November 17th
zacks.com · Nov 17
Best Growth Stocks to Buy for November 13th
zacks.com · Nov 13
Best Growth Stocks to Buy for November 11th
zacks.com · Nov 11
Best Growth Stocks to Buy for November 9th
zacks.com · Nov 9
Bausch + Lomb: Profits Return In Q3 As A Recovery Story, While Pipeline Grows
seekingalpha.com · Nov 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.